|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SOX15 |
Gene summary for SOX15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SOX15 | Gene ID | 6665 |
| Gene name | SRY-box transcription factor 15 | |
| Gene Alias | SOX20 | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O60248 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6665 | SOX15 | LZE4T | Human | Esophagus | ESCC | 1.03e-23 | 1.42e+00 | 0.0811 |
| 6665 | SOX15 | LZE7T | Human | Esophagus | ESCC | 3.34e-09 | 1.38e+00 | 0.0667 |
| 6665 | SOX15 | LZE22D1 | Human | Esophagus | HGIN | 1.34e-02 | -1.76e-01 | 0.0595 |
| 6665 | SOX15 | LZE24T | Human | Esophagus | ESCC | 2.15e-11 | 9.96e-01 | 0.0596 |
| 6665 | SOX15 | P1T-E | Human | Esophagus | ESCC | 7.42e-07 | 1.14e+00 | 0.0875 |
| 6665 | SOX15 | P2T-E | Human | Esophagus | ESCC | 4.48e-26 | 5.68e-01 | 0.1177 |
| 6665 | SOX15 | P4T-E | Human | Esophagus | ESCC | 6.14e-42 | 1.99e+00 | 0.1323 |
| 6665 | SOX15 | P5T-E | Human | Esophagus | ESCC | 1.12e-08 | 4.86e-01 | 0.1327 |
| 6665 | SOX15 | P9T-E | Human | Esophagus | ESCC | 1.83e-08 | 5.71e-01 | 0.1131 |
| 6665 | SOX15 | P10T-E | Human | Esophagus | ESCC | 1.02e-16 | 3.79e-01 | 0.116 |
| 6665 | SOX15 | P11T-E | Human | Esophagus | ESCC | 8.98e-17 | 2.31e+00 | 0.1426 |
| 6665 | SOX15 | P12T-E | Human | Esophagus | ESCC | 5.25e-11 | -4.42e-01 | 0.1122 |
| 6665 | SOX15 | P15T-E | Human | Esophagus | ESCC | 1.22e-19 | 9.08e-01 | 0.1149 |
| 6665 | SOX15 | P16T-E | Human | Esophagus | ESCC | 5.19e-31 | 8.68e-01 | 0.1153 |
| 6665 | SOX15 | P17T-E | Human | Esophagus | ESCC | 1.01e-02 | 7.80e-01 | 0.1278 |
| 6665 | SOX15 | P19T-E | Human | Esophagus | ESCC | 3.93e-09 | 2.61e+00 | 0.1662 |
| 6665 | SOX15 | P20T-E | Human | Esophagus | ESCC | 1.55e-43 | 1.48e+00 | 0.1124 |
| 6665 | SOX15 | P21T-E | Human | Esophagus | ESCC | 3.36e-44 | 1.71e+00 | 0.1617 |
| 6665 | SOX15 | P22T-E | Human | Esophagus | ESCC | 1.25e-87 | 1.99e+00 | 0.1236 |
| 6665 | SOX15 | P23T-E | Human | Esophagus | ESCC | 1.24e-09 | 8.11e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000632516 | Esophagus | HGIN | chromatin organization | 92/2587 | 409/18723 | 1.05e-06 | 4.16e-05 | 92 |
| GO:000170118 | Esophagus | HGIN | in utero embryonic development | 77/2587 | 367/18723 | 9.56e-05 | 2.05e-03 | 77 |
| GO:000189019 | Esophagus | HGIN | placenta development | 35/2587 | 144/18723 | 5.02e-04 | 7.31e-03 | 35 |
| GO:000189218 | Esophagus | HGIN | embryonic placenta development | 23/2587 | 82/18723 | 5.47e-04 | 7.73e-03 | 23 |
| GO:00605379 | Esophagus | HGIN | muscle tissue development | 76/2587 | 403/18723 | 2.67e-03 | 2.63e-02 | 76 |
| GO:00147068 | Esophagus | HGIN | striated muscle tissue development | 72/2587 | 384/18723 | 3.94e-03 | 3.56e-02 | 72 |
| GO:006145819 | Esophagus | HGIN | reproductive system development | 78/2587 | 427/18723 | 5.53e-03 | 4.52e-02 | 78 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:0001890110 | Esophagus | ESCC | placenta development | 98/8552 | 144/18723 | 4.46e-08 | 8.11e-07 | 98 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
| GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
| GO:003109910 | Esophagus | ESCC | regeneration | 122/8552 | 198/18723 | 4.26e-06 | 4.57e-05 | 122 |
| GO:00900689 | Esophagus | ESCC | positive regulation of cell cycle process | 142/8552 | 236/18723 | 4.79e-06 | 5.08e-05 | 142 |
| GO:000189219 | Esophagus | ESCC | embryonic placenta development | 57/8552 | 82/18723 | 1.06e-05 | 1.01e-04 | 57 |
| GO:00485687 | Esophagus | ESCC | embryonic organ development | 228/8552 | 427/18723 | 7.28e-04 | 3.79e-03 | 228 |
| GO:00454454 | Esophagus | ESCC | myoblast differentiation | 52/8552 | 84/18723 | 1.98e-03 | 8.90e-03 | 52 |
| GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
| GO:00607065 | Esophagus | ESCC | cell differentiation involved in embryonic placenta development | 18/8552 | 25/18723 | 7.04e-03 | 2.56e-02 | 18 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| SOX15 | INCAF | Endometrium | EEC | SIAH2,PENK,DPT, etc. | 4.02e-01 |  |
| SOX15 | CD8TRM | Esophagus | ESCC | SHISA2,CASP6,NECAB3, etc. | 5.08e-01 |  |
| SOX15 | MSC | Esophagus | ESCC | C7,SCN7A,ABCA8, etc. | 2.62e-01 | |
| SOX15 | MSC.MVA | Oral cavity | OSCC | AKR1C2,KRT5,C19orf33, etc. | 2.84e-01 |  |
| SOX15 | STM | Prostate | ADJ | SERPINB5,GJB5,MYH11, etc. | 4.41e-01 |  |
| SOX15 | STM | Prostate | Tumor | SERPINB5,GJB5,MYH11, etc. | 1.97e-01 |  |
| SOX15 | URO | Prostate | Tumor | SERPINB5,GJB5,MYH11, etc. | 1.30e-01 | |
| SOX15 | INMON | Skin | ADJ | RIN1,GJB2,HOPX, etc. | 1.99e-01 |  |
| SOX15 | CD8TRM | Skin | AK | RIN1,GJB2,HOPX, etc. | 3.30e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SOX15 | SNV | Missense_Mutation | c.38N>T | p.Ser13Ile | p.S13I | O60248 | protein_coding | deleterious_low_confidence(0) | benign(0.125) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | ||
| SOX15 | SNV | Missense_Mutation | novel | c.168C>G | p.Phe56Leu | p.F56L | O60248 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-S3-AA15-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| SOX15 | deletion | Frame_Shift_Del | novel | c.252delN | p.Ala85ArgfsTer146 | p.A85Rfs*146 | O60248 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SOX15 | SNV | Missense_Mutation | rs755842358 | c.623N>T | p.Thr208Ile | p.T208I | O60248 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SOX15 | SNV | Missense_Mutation | c.413N>A | p.Arg138Lys | p.R138K | O60248 | protein_coding | tolerated_low_confidence(0.81) | benign(0.01) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SOX15 | SNV | Missense_Mutation | c.413N>C | p.Arg138Thr | p.R138T | O60248 | protein_coding | tolerated_low_confidence(0.47) | benign(0.001) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SOX15 | SNV | Missense_Mutation | c.430G>A | p.Gly144Ser | p.G144S | O60248 | protein_coding | tolerated_low_confidence(0.17) | benign(0.009) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SOX15 | deletion | Frame_Shift_Del | c.342delN | p.Asp115ThrfsTer116 | p.D115Tfs*116 | O60248 | protein_coding | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |||
| SOX15 | deletion | In_Frame_Del | c.142_144delNNN | p.Lys48del | p.K48del | O60248 | protein_coding | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |||
| SOX15 | SNV | Missense_Mutation | novel | c.193N>T | p.Arg65Cys | p.R65C | O60248 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |